IN2012DN01234A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01234A
IN2012DN01234A IN1234DEN2012A IN2012DN01234A IN 2012DN01234 A IN2012DN01234 A IN 2012DN01234A IN 1234DEN2012 A IN1234DEN2012 A IN 1234DEN2012A IN 2012DN01234 A IN2012DN01234 A IN 2012DN01234A
Authority
IN
India
Prior art keywords
compounds
formula
well
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Gregory Martin Benson
Konrad Bleicher
Song Feng
Uwe Grether
Bernd Kuhn
Rainer E Martin
Jean-Marc Plancher
Hans Richter
Markus Rudolph
Sven Taylor
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN01234A publication Critical patent/IN2012DN01234A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN1234DEN2012 2009-09-29 2010-09-27 IN2012DN01234A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09171700 2009-09-29
PCT/EP2010/064217 WO2011039130A1 (en) 2009-09-29 2010-09-27 New benzimidazole derivatives and their use as fxr agonists

Publications (1)

Publication Number Publication Date
IN2012DN01234A true IN2012DN01234A (enExample) 2015-05-15

Family

ID=43033176

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1234DEN2012 IN2012DN01234A (enExample) 2009-09-29 2010-09-27

Country Status (12)

Country Link
US (1) US8309581B2 (enExample)
EP (1) EP2483247A1 (enExample)
JP (1) JP5503007B2 (enExample)
KR (1) KR101477872B1 (enExample)
CN (1) CN102574812B (enExample)
AU (1) AU2010303146A1 (enExample)
BR (1) BR112012006986A2 (enExample)
CA (1) CA2772815A1 (enExample)
IL (1) IL218037A0 (enExample)
IN (1) IN2012DN01234A (enExample)
MX (1) MX2012002479A (enExample)
WO (1) WO2011039130A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377523B (es) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
CN108072684B (zh) * 2016-11-11 2020-06-16 中国科学院广州生物医药与健康研究院 法尼醇x受体的新配体及其筛选方法和应用
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Pparアゴニストとfxrアゴニストとの組合せ
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
BRPI0713946A2 (pt) 2006-06-29 2012-12-04 Hoffmann La Roche compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr, e uso dos compostos
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
JP5204232B2 (ja) * 2007-08-27 2013-06-05 エフ.ホフマン−ラ ロシュ アーゲー Fxrアゴニストとして使用されるベンゾイミダゾール誘導体
AU2008323017B2 (en) * 2007-11-15 2012-12-20 F. Hoffmann-La Roche Ag Methyl-benzimidazole derivatives
CN102149688B (zh) * 2008-09-11 2014-11-19 霍夫曼-拉罗奇有限公司 新型苯并咪唑衍生物
CN102186830A (zh) * 2008-10-15 2011-09-14 霍夫曼-拉罗奇有限公司 新型苯并咪唑衍生物

Also Published As

Publication number Publication date
CN102574812A (zh) 2012-07-11
US8309581B2 (en) 2012-11-13
AU2010303146A1 (en) 2012-04-19
MX2012002479A (es) 2012-03-26
JP5503007B2 (ja) 2014-05-28
US20110077273A1 (en) 2011-03-31
EP2483247A1 (en) 2012-08-08
JP2013505977A (ja) 2013-02-21
IL218037A0 (en) 2012-04-30
HK1171746A1 (zh) 2013-04-05
KR101477872B1 (ko) 2014-12-30
CN102574812B (zh) 2016-03-30
BR112012006986A2 (pt) 2016-04-12
KR20120063536A (ko) 2012-06-15
WO2011039130A1 (en) 2011-04-07
CA2772815A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
IN2012DN03337A (enExample)
MY138941A (en) Aryl-pyridine derivatives
MX2010005824A (es) Derivados de aminotiazol.
UA102310C2 (ru) Гетероциклические сульфонамиды, их применение и фармацевтические композиции
MX2011012017A (es) Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).
TW200738241A (en) Pyridazine derivatives
GEP20125487B (en) Organic compounds and their use
PH12013500942A1 (en) Triazolopyridine compounds
IN2012DN01232A (enExample)
TW200626558A (en) Indazolone derivatives
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
MX2009010218A (es) Derivados de aza-piridopirimidinona.
TW200833324A (en) Sulfonamide derivatives
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
IN2012DN00765A (enExample)
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW200745032A (en) Novel heterobicyclic derivatives
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
MX2010005714A (es) Compuestos de piridina.
MX2010001742A (es) Nuevos derivados de piperazina-amida.
PH12014501540A1 (en) 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives
GEP201606545B (en) 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
TW200616976A (en) Pyrimidine derivatives